Aniara News

HYPHEN BioMed Documents Now In French & Spanish

2011-06-17T17:03:49.852-04:00

Aniara is happy to announce that many of the HYPHEN BioMed package inserts are now available in English, French and a few in Spanish. HYPHEN BioMed MSDS are available in English and French. To locate the French and Spanish versions of these documents, please click on the package insert or MSDS links on the individual Aniara product pages. The French and Spanish versions are located at the end of the Engish document.

We are glad that we can provide these files in French and Spanish.

WING YOUR WAY TO KYOTO FOR ISTH 2011!

2010-10-04T00:00:00.000-04:00

All Expenses Paid Trip Awaits Winner Of Aniara Contest

ANIARA, exclusive North American distributor for HYPHEN BioMed, a leader in research and diagnostic reagents for thrombosis – haemostasis and autoimmunity, announces your chance to win an all expenses paid trip for one to the XXIII Congress of the International Society on Thrombosis and Haemostasis and 57th SSC Meeting in Kyoto Japan, July 23-28, 2011.

ANIARA will soon begin accepting contest registration via www.aniara.com. Interested parties are urged to visit frequently to find an “Enter To Win” link that will be posted on the site Home Page. Eligible contestants must work in the field of Haemostasis/Thrombosis as a practicing Lab Tech, Clinician, or Research Tech.

The prize includes airfare, meeting registration fees, lodging, and food. Value of the prize is not to exceed $15,000.00. All registrants must agree to posted Terms & Conditions.

The winner will be selected by random drawing, March, 2011.

Kyoto, one of Japan's major cities, offers an intriguing blend of both the modern and the timeless. Be there!

Evaluation of new USP Heparin Standard and NIBSC

2009-11-30T00:00:00.000-05:00

HYPHEN BioMed evaluation :
A verification has been conducted using HYPHEN heparin assay kits (anti-IIa method, kit A221025) using the new USP vs the NIBSC UFH standard, and including HYPHEN UFH internal reference calibrators and quality controls, to verify homogeneous performance.

Products:
Reference Product IVD (510k) IVD (CE mark) RUO
A222301 Biophen UFH Calibrator x x
A223101 Biophen UFH Control x x
A221025 Biophen Heparin antiIIa (2 stages) x

Summary of results:

Conclusion:

With the tested A221025 device, the measured values are in compliance with the expected values, and homogeneous between the new USP standard, the WHO/NIBSC standard for UFH, and internal reference standards and quality controls validated in HYPHEN.

Using A221025 kit, the measured values for the USP standard are measured in compliance with the expected values (theorical expected concentrations of the tested dilutions, from nominal concentration attributed as per USP method).

Measuring the APC Resistance V Associated with Factor V-L, Quantitatively with the Hyphen Biomed kit

2009-11-04T00:00:00.000-05:00

Measuring the APC Resistance V associated with Factor V-L, quantitatively
With The Hyphen Biomed Kit
FDA Approved (510K)

Click here for product page

Clinical background

The Factor V-L is insensitive to the action of Activated Protein C. Its presence induces a prolonged coagulant activity in blood (due to a prolonged survival of Factor Va activity), following activation of coagulation. Patients with Factor V-L (mutation R506Q), are exposed to an increased thrombotic risk. This risk, already present in heterozygous patients, where the Normal Factor V and Factor V-L are both present, is strongly enhanced in homozygous patients, who only have Factor V-L.
HEMOCLOT Quanti. V-L (ACK065L) kit is a clotting method proposed for measuring Factor V-L (Factor V Leiden) concentration in citrated plasma, by its resistance to the action of Activated Protein C (APC). The assay is performed in the presence of Activated Protein C. In presence of APC and Protein S (in excess), the prolongation of clotting time is directly related to the concentration of Normal Factor V, and inversely related to the amount of Factor V-Leiden (mutation R506Q).inhibition IIa Fibrinogen (in excess) Fibrin (Coagulation) II (in excess) PLPCa2+Or No inhibition PLPCa2+APC / PSXaVV-L

Assay characteristics

.Quantitative reagent for measuring Factor V-L.
.No interference of plasma factor deficiencies (Other than that of Factor V).
.Excellent discrimination between Heterozygous, Homozygous and Normals.
.Single test method performed with only a Clotting Time (CT).

Assay principle

The HEMOCLOT QuantiV-L Kit is a clotting method, triggered by purified Factor Xa, containing Phospholipids and Calcium, and is performed on the diluted tested plasma, in presence of Activated Protein C and Protein S. In the first step, the diluted plasma is mixed with purified clotting Factors (clotting mixture containing Prothrombin, Fibrinogen, Protein S and Activated Protein C (APC)), in a constant and optimized concentration. Then, the purified Factor Xa in presence of Phospholipids (PLP) is added. Clotting is initiated by the addition of Calcium (Ca2+). The clotting time is then recorded. Clotting time measured is inversely proportional to the concentration of factor V-L. There is an inverse linear relationship, on a bi logarithmicgraph paper, between the factor V-L concentration and the corresponding clotting time.

HEMOCLOT Quanti. V-L is now CE Marked and 510(k) approved

For more product information please follow this link.

Jonas Kingo
Executive Vice President of Global Marketing and Sales
www.aniara.com
A true partnership is a win win for everybody

USP compliant anti IIa and anti Xa Heparin kits now available from Aniara

2009-08-04T00:00:00.000-04:00

ANIARA OFFERS THE MOST COMPLETE RANGE OF CHROMOGENIC ASSAYS OR BIOREAGENTS FOR HEPARIN TESTING FROM HYPEN BIOMED.

TWO-STAGE METHODS:

Anti-Xa: (USP COMPLIANT KIT)
Working range 0 to 2 IU/mL in plasma (1:10),
or 0 to 0.2 IU/mL in purified systems.
The method of choice for testing heparin, in
compliance with pharmacopoeias.
Can be used for pentasaccharide
(Arixtra /Fondaparinux) and Orgaran.
Exogenous AT III supplied in the assay.

Anti-IIa: (USP COMPLIANT KIT)
Working range 0 to 1 IU/mL in plasma
(1:25), or 0 to 0.04 IU/mL in purified systems.
Highly sensitive; can be used for testing
Heparin, in compliance with pharmacopoeias.
Working range can be adjusted through the
dilution used.
Exogenous AT III supplied in the assay.

KINETICS/COMPETITIVE METHODS:

Anti-Xa:
The method of choice for the current testing
of heparin in clinical samples.
Can be used for UFH, LMWH (hybrid curve),
Orgaran or Arixtra, on an extended range
(0 to 2 IU/mL).
Endogenous AT III present in the tested
plasma.
Assay variant with exogenous AT III.
Anti-IIa (USP COMPLIANT KIT)
The method of choice for testing heparin
anti-IIa activity on a wide range of
concentrations, without diluting the sample (0
to 6 IU/mL).
Appropriate assay for testing drugs in
purified systems or coated devices.
Exogenous AT III supplied in the assay.
In compliance with the latest USP guidelines. Our thrombin is in highly purified alpha format optimized for chromogenic assays. All assays can be used on laboratory automated instruments A full range of calibrators and controls (UFH/LMWH/Arixtra /Orgaran), established against the NIBSC International Standards for UFH and LMWH, are available.
*WE ALSO OFFFER A FULL RANGE OF BIOREAGENTS AS WELL FOR HEPARIN TESTING.

NOW FDA approved for clinical use Measuring the APC Resistance associated with Factor V-L, quantitatively Second generation screenig assay for APC-R.

2009-05-11T00:00:00.000-04:00

NEW CONCEPT FOR FV-LEIDEN Second generation for screening for APC-R. Reducing cost up to 50%/test compared to the old way of screening for APC-R. This new method is only available through Hyphen BioMed/Aniara.

For more information please follow the link below:

http://www.aniara.com/mm5/merchant.mvc?Screen=PROD&Store_Code=ANIA&Product_Code=ACK065K&Category_Code=FACTORVLEIDEN

HEMOCLOT Quanti. V-L (ACK065L) kit is a clotting method proposed for measuring Factor V-L (Factor V Leiden) concentration in citrated plasma, by its resistance to the action of Activated Protein C (APC). The assay is performed in the presence of Activated Protein C. In presence of APC and Protein S (in excess), the prolongation of clotting time is directly related to the concentration of Normal Factor V, and inversely related to the amount of Factor V-Leiden (mutation R506Q).

Assay characteristics

- Quantitative reagent for measuring Factor V-L.

- No interference of plasma factor deficiencies (Other than that of Factor V).

- Excellent discrimination between Heterozygous, Homozygous and Normal's.

- Single test method performed with only a Clotting Time (CT).

Literature Links:

- Quantitative Assay for Measuring Factor V-Leiden Concentration in Plasma by its Resistance to the Action of Activated Protein C - Hemoclot Quanti-V-L (Ref. ACK065K)

- New Quantitative Assay for Factor V-Leiden - Measuring APC Resistance Associated with Factor V-Leiden Quantitatively (Ref. ACK061K/ACK061L)

- Quantitative Measurement Of Factor V-Leiden With a New, One Step, Calibrated, Clotting Assay (Ref. ACK061K/ACK061L)

- Classification of Factor V-Leiden Carriers by Quantitatively Measuring it's Procoagulant Activity Comparatively to that of Factor V (Ref. ACK065K, ACK061K, ACK071K and ARK009A)

- Quantitative Measurement of Factor V Leiden in Heterozygous and Homozygous Patients for the R506Q Factor V Mutation (Ref. ACK065K, ACK061K, ACK071, ARK009A)

ISTH Poster:

http://www.aniara.com/pdf/FVL.pdf

Product SKU and Pricing Information

HEMOCLOT Quanti V-L 510K/CE Cleared Clotting Set of 3x20 tests ACK065K $225

Factor V-L Calibrator 510K/CE Cleared Set of 3 (4x1 ml) ASC065K $125

V-L CAL (Undiluted) 510K/CE Cleared 2x3x0.5 ml A222401 $125

BIOPHEN Normal Control Plasma 510k/CE Cleared 12x1 ml A223201 $175

Act PC-r Control Plasma 510K/CE Cleared 12x0.5 ml A223405 $195

Heparin Anti IIa and Anti Xa activity assays and reagents from Aniara

2009-03-10T00:00:00.000-04:00

Aniara is happy to announce a full assortment of kits and reagents for testing Heparin anti IIa and anti Xa activity in purified or plasma system. With the new guidelines from USP recommending now using a Heparin anti IIa activity assay and also doing a ratio with anti IIa and anti Xa.

We are please to inform all industrial clients, that need to implement this by August, 09. Aniara/Hyphen BioMed offer a two day training session at Hyphen BioMed's facility's in France. The meeting will discuss our products and include a wet shop where you will get the chance to setup the anti IIa and anti Xa assays either by using our kits or our bio reagents based on the USP guidelines or EP guidelines.

Aniara is happy to be in the forefront and the leader in this field and is happy with helping updating your current QC methods to meet the new guidelines in time.

For more information about these products please follow the link:

For more information or if you would like your local Account Executive to contact you please send an email to info@aniara.com

Thank you

Aniara

Another Happy Aniara Customer

2009-02-13T00:00:00.000-05:00

I would also like to commend your company for expediting the shipment of the Zymutest HIA IgG, IgA, IgM kit during the holiday period. We had a very sick child for whom doctors need this testing. Your company came through with overnight shipping and we were able to do the test the next day. We really appreciate this kind of customer service.

Thank you,

Diane Meares, MT (ASCP) SH
Senior Medical Technologist
Special Hematology Laboratory
Wake Forest University Health Sciences

Aniara Keeps growing- Please welcome our new colleague

2009-01-12T00:00:00.000-05:00

Aniara is very happy to inform that we have added another exceptional team member to our group.

Her name is Kathaleen Atkinson and she will be responsible for Sales and customer service in United States.

She has 21 years of experience as a Sales Representative for MERCK Pharmaceuticals and she has a Nurse background with Lab experience. We are very excited about her joining our growing family.

Jonas Kingo
Executive Vice President of Global Marketing and Sales
www.aniara.com
A true partnership is a win win for everybody!

Aniara 2008 Grant Winner is Dr. Krikun

2008-11-20T00:00:00.000-05:00

Aniara Grant
2008 Coagulation Grant Winner
Aniara is happy to announce the winner of the 2008 Aniara grant in the amount of $5000.
Endometriosis is a major women's health problem, characterized by the presence of endometrial tissue outside the uterine cavity causing pelvic adhesions, focal bleeding, infertility and pain. Its diagnosis is exceedingly difficult as symptoms are non-specific and definitive diagnoses require laparoscopy. Irrespective of etiology, long-term survival of endometriotic implants is associated with marked angiogenesis. In certain malignant and inflammatory states, tissue factor (TF) induces a potent pro-angiogenic milieu. We have previously shown that eutopic endometria from women with endometriosis display increased endometrial glandular epithelial cell TF expression. Moreover, endometriotic implants display aberrant expression of TF in endothelial cells and intense expression in macrophages. By contrast, in healthy women, TF levels are highest in the stromal cells of eutopic endometrium with minimal expression in epithelial cells. In the circulation, TF is associated with microvesicles. Inflammation results in increased shedding of microvesicles into the circulation. The central hypothesis of this proposal is that growth and angiogenesis of ectopic endometriotic tissue is associated with enhanced TF expression in endometrial epithelial, stromal and endothelial cells as well as leukocytes resulting in excessive shedding of TF-containing microvesicles into the circulation. Hence, we propose to study a cohort of women with and without endometriosis to establish if this disease can be detectable without the need for surgery.
In summary we will collect blood and intraperitoneal fluid and test for total microparticle expression in controls vs. patients. We will assess the percent of TF-expressing microparticles and will try to identify the cellular source of the microparticles. These studies represent bench-to-bedside translational research and have the potential to result in non-invasive methods of detection as well as the ability to follow progression of the disease.

Graciela Krikun, PhD

Dept. Ob/Gyn & Rep. Endo.

Director: Unit of Endometrial angiogenesis and hemostasis

Yale University, SOM

New Haven, CT. USA

The 2008 CHTAE Winner is Kelly Townsend from TriCore Reference

2008-11-18T00:00:00.000-05:00

2008 Lab Tech Award Winner
Congratulations to Ms Kelly Townsend - 2008 Labtech Award Winner
The 2008 Coagulation Hemostasis Technologist Award of Excellence (CHTAE) selection committee received and reviewed the nominations of fourteen hemostasis and coagulation technologists. The committee recognizes the high level of commitment to provide excellent patient care and quality laboratory medicine of all the nominated technologists this year.The selection committee is pleased to announce that Ms. Kelly Townsend, from TriCore Reference Labs in Albuquerque, NM, USA has been selected as the recipient of the 2008 CHTAE.Kelly's Medical Director, Dr. Kendall Crookston, MD, PhD, summarized Kelly's wide range of responsibilities. Kelly is responsible for the operation of a large special coagulation laboratory that services a high percentage of the population in the state of New Mexico. In addition, Kelly is a consultant for upwards of seventeen off-site hospitals and laboratories affiliated with their organization. Dr. Crookston wrote that Kelly has "remarkable insight into quality issues, compliance and meeting the needs of both physicians and patients". Kelly is a volunteer faculty member at the University of New Mexico Department of Pathology and the Transfusion Medicine Fellowship Training program.The committee agreed that Kelly demonstrates the attributes that personifies an excellent coagulation and hemostasis technologist and is deserving of the 2008 CHTAE. The committee agreed that Kelly's approachable nature and empathy, her knowledge base, as well as her commitment to provide excellent patient care and quality laboratory medicine, has enabled Kelly to become an essential team member for the provision of health care in the state of New Mexico. The committee recognizes Kelly's strong leadership abilities and her contributions to the education of technologists, medical students and residents in the area of coagulation and hemostasis.
Congratulations Kelly! Sincerely,Karen Moffat, Chairpersonon behalf of the 2008 CHTAE Selection Committee

Aniara reduces price on two clinical products Biophen Protein C and ATIII kits.

2008-11-11T00:00:00.000-05:00

Aniara is happy to be able to reduce cost on two of our products. These product are very similar in performance with most companies. Most labs do not want to change them because they are working well. I only ask that you do a quick calculation how much you pay per test with your current kit and compare it with our per test cost and then multiply it with amount of tests you use per year to see how much money you can save your lab. By changing to the Biophen Protein C or ATIII kit. You will keep or improve the quality of the testing, while you will at the same time save money for your lab. For clinical evaluation we will provide a free kit if it is used within 4 weeks of the request. We have applications for most instrument for these products.

Biophen Protein C 2.5 is now $195/kit or $2.60/test
For more info:
Biophen Protein C 5 is now $495/kit or $1.77/test
For more info:
Biophen ATIII 2.5 is now $65/kit or $1.30/test
For more info:
Biophen ATIII 5 is now $250/kit or $1.25/test
For more info:

6560 Gove Ct
Mason, OH 45040
513-770-1980 North America
+46 (0) 150-27020 Europe
info@aniara.com
www.aniara.com

Aniara Upgrades Website

2008-10-29T00:00:00.000-04:00

Aniara is happy to introduce our new upgraded website www.aniara.com. We have worked hard over the last year taking feedback from customer of ours and used that to upgrade our site.

The main goal of our upgrade was to make the site even easier for our customer to find and buy our products. Also prepare our site for some new exciting features we will add over the next year. Some features we have already implemented are:

Easier product navigation
You can now review our products
Recommend a specific product to a college of yours from our site.
Easier shopping cart and checkout.
We now can offer academic discount coupons that you can use at our online store.

Aniara is grateful for all support and feedback from our customers and we hope you enjoy browsing our upgraded www.aniara.com

Jonas Kingo

Executive Vice President

Aniara Diagnostica